{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Herpesvirus+2%2C+Human&page=2",
    "query": {
      "condition": "Herpesvirus 2, Human",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Herpesvirus+2%2C+Human&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T14:56:43.302Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05703607",
      "title": "A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Shingles",
        "Herpes Zoster Infection",
        "Human"
      ],
      "interventions": [
        {
          "name": "Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 1: PF-07915234: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 2: PF-07921188: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 3: PF-07921186: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 484,
      "start_date": "2023-01-25",
      "completion_date": "2025-09-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 35,
      "location_summary": "Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05703607"
    },
    {
      "nct_id": "NCT04950712",
      "title": "An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Herpes Genitalis"
      ],
      "interventions": [
        {
          "name": "Blood sampling",
          "type": "PROCEDURE"
        },
        {
          "name": "Anogenital lesion swab collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 537,
      "start_date": "2021-06-09",
      "completion_date": "2024-03-14",
      "has_results": false,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 22,
      "location_summary": "Long Beach, California • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04950712"
    },
    {
      "nct_id": "NCT05592626",
      "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Genital Neoplasm, Female",
        "Urogenital Neoplasms",
        "Lung Neoplasm",
        "Neoplasms by Site",
        "Papillomavirus Infection",
        "Epstein-Barr Virus Infections",
        "Carcinoma",
        "Neoplasms",
        "Vulvar Neoplasms",
        "Vulvar Diseases",
        "Abdominal Neoplasm"
      ],
      "interventions": [
        {
          "name": "STAR0602",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marengo Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2023-01-04",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 18,
      "location_summary": "Loma Linda, California • Sacramento, California • Denver, Colorado + 14 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05592626"
    },
    {
      "nct_id": "NCT00362297",
      "title": "Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "acyclovir",
          "type": "DRUG"
        },
        {
          "name": "valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2006-09",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2021-11-18",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362297"
    },
    {
      "nct_id": "NCT05432583",
      "title": "A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "BNT163",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 318,
      "start_date": "2022-12-08",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 6,
      "location_summary": "Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05432583"
    },
    {
      "nct_id": "NCT00231049",
      "title": "Trial Evaluating Safety, Tolerability and Immune Response of AG-707",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "AG-707",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2006-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-10-27",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00231049"
    },
    {
      "nct_id": "NCT00004061",
      "title": "Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Oral Complications"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "palifermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 111,
      "start_date": "1999-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004061"
    },
    {
      "nct_id": "NCT05871541",
      "title": "A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Zoster (HZ)",
        "Shingles",
        "Infectious Disease"
      ],
      "interventions": [
        {
          "name": "JCXH-105",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Control (Shingrix)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Immorna Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "50 Years to 69 Years"
      },
      "enrollment_count": 75,
      "start_date": "2023-05-26",
      "completion_date": "2024-03-25",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • Tampa, Florida • Berlin, New Jersey",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05871541"
    },
    {
      "nct_id": "NCT03103971",
      "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Adult Acute Lymphoblastic Leukemia",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent Transformed Non-Hodgkin Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements"
      ],
      "interventions": [
        {
          "name": "Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2017-11-03",
      "completion_date": "2024-03-23",
      "has_results": false,
      "last_update_posted_date": "2024-04-10",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03103971"
    },
    {
      "nct_id": "NCT04294030",
      "title": "NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HSV-2 Infection",
        "Herpes Simplex Virus Infection"
      ],
      "interventions": [
        {
          "name": "Diagnostic Test: NOWDx HSV-2 Test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NOWDiagnostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-03-01",
      "completion_date": "2023-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-02-29",
      "last_synced_at": "2026-07-23T14:56:43.302Z",
      "location_count": 3,
      "location_summary": "Tempe, Arizona • Coral Gables, Florida • Lexington, Kentucky",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04294030"
    }
  ]
}